HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.

AbstractBACKGROUND:
Clostridium botulinum is an obligate anaerobic, Gram positive bacterium that secretes extremely toxic substances known as botulinum neurotoxins (BoNTs) that cause serious paralytic illness called botulism. Based upon the serological properties, these neurotoxin have been classified into seven serotypes designated from A to G. Due to extreme toxicity of BoNTs, these neurotoxins have been designated as category A biowarfare agents. There is no commercial neutralizing antibody available for the treatment of botulism. Hence there is an urgent need to develop therapeutic intervention for prevention and cure of botulism within short period. BoNT antiserum injection is still the effective treatment.
METHOD:
In the present study, the recombinant light chain of BoNT/E was successfully purified in soluble form. The purified rBoNT/E LC was used for the generation of polyclonal antibody in rabbit. In order to find out the neutralizing capacity of generated antisera, rabbit antiserum was incubated with 20 LD50 of botulinum neurotoxin type E for 1 hour at 37°C and then injected intraperitoneally (IP) into mice. Further in another set of experiments antiserum was administered in different ways that included administration of - antiserum and BoNT/E toxin simultaneously without preincubation, one after another at the same and different time points for its therapeutic ability. To find out cross neutralization capacity, rBoNT/E LC antiserum was pre-incubated with 5 LD50 of BoNT/A, BoNT/B, BoNT/F and then injected (IP) into mice. In all the cases mice were observed continuously for 96 hours.
RESULT:
The results clearly indicate that developed polyclonal rabbit antiserum showed serotype specific neutralization of BoNT/E toxin only but not of BoNT/A, BoNT/B and BoNT/F.
CONCLUSION:
The developed antibodies will be used for preventive and therapeutic intervention of type 'E' botulism.
AuthorsSarita Rani, S Ponmariappan, Arti Sharma, D V Kamboj, A K Jain
JournalProtein and peptide letters (Protein Pept Lett) Vol. 24 Issue 6 Pg. 495-502 ( 2017) ISSN: 1875-5305 [Electronic] Netherlands
PMID28260503 (Publication Type: Journal Article)
CopyrightCopyright© Bentham Science Publishers; For any queries, please email at [email protected].
Chemical References
  • Antibodies, Neutralizing
  • Single-Chain Antibodies
  • Botulinum Toxins
  • botulinum toxin type E
Topics
  • Animals
  • Antibodies, Neutralizing (immunology, therapeutic use)
  • Botulinum Toxins (antagonists & inhibitors, immunology)
  • Botulism (drug therapy, immunology, microbiology)
  • Clostridium botulinum (immunology, pathogenicity)
  • Mice
  • Rabbits
  • Serogroup
  • Single-Chain Antibodies (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: